Back to search

Boston University

The role of opioid signaling on HIV-1 infection in microglia

Abstract

dc:description.abstract

The growing syndemic of HIV-1 and opioid use disorder (OUD) remains a public health concern. Injection drug use accounts for 12% of global HIV-1 transmissions, and 30% of people who inject drugs have HIV-1. People living with HIV-1 (PWH) and chronically using opioids have elevated risks of developing HIV-associated neurological disorders (HAND), characterized by chronic neuroinflammation and neurocognitive deficits. Microglia, resident brain macrophages, are the principal CNS HIV-1 reservoir that regulates neuroinflammation and are thought to contribute to HAND development. Microglia express μ opioid receptor, MOR, though the effects of opioids on HIV-1 replication and their immunomodulatory effects in microglia remain unclear. Our previous research has shown that HIV-1 intron-containing RNA (icRNA) expression infection of induced pluripotent stem cell-derived microglia (iMGs) triggers inflammatory responses. Thus, we evaluated the effects of morphine on MOR-expressing iMGs before and post-HIV-1 infection establishment. MOR activation upon morphine pretreatment before HIV-1 infection enhanced viral reverse transcription (RT), integration of intact proviruses, icRNA transcription, and p24Gag secretion in iMGs, which was blocked by naloxone treatment, a MOR antagonist. MOR activation also enhances Akt activation by phosphorylation in a PI3K-dependent manner and PI3K inhibitors suppress HIV-1 replication in microglia. In contrast, morphine treatment did not modulate HIV-1 infection in MOR-deficient macrophages. Interestingly, exogenous MOR expression in macrophages conferred morphine-mediated enhancement of HIV-1 RT, proviral establishment, icRNA, and p24Gag secretion, suggesting that MOR expression is essential for transducing morphine-modulating effects on HIV-1 replication. Importantly, morphine enhanced HIV-1 icRNA-induced IP-10, IL-8, and MCP-1 secretion in microglia, which was suppressed by a MOR antagonist, naloxone, and a PI3K inhibitor, wortmannin. These results indicate that MOR signaling and HIV-1 synergistically activate PI3K-Akt signaling in microglia, thereby exacerbating virus-induced inflammatory responses. Bulk transcriptomic analysis of HIV-1-infected and morphine-treated microglia revealed activation of diverse neuroinflammatory pathways, though, surprisingly, there was minimal overlap between morphine- and HIV-infection-dependent pathway induction. For instance, morphine treatment skewed microglia phenotypes towards a disease-associated state with elevated expression of pathways associated with DNA damage response, phagocytosis, inflammation, and RNA metabolism, while HIV-infection was primarily associated with upregulation of inflammatory and type I interferon responses. Furthermore, morphine enhanced the expression of genes associated with Alzheimer’s disease and elevated inflammatory responses mediated the development of disease-associated microglia (DAM) phenotype. Enriched pathways upon morphine treatment that were associated with this dysfunctional microglia-like phenotype include hyper-cell adhesion, complement activation, cytoskeleton-associated cell protrusion, phagocytosis, and synaptic plasticity, which may contribute to loss of homeostatic functions in microglia and promote excessive phagocytosis-dependent synapse loss and cognitive decline. Follow-up proteomic analyses revealed that MOR antagonists, naloxone and CTOP, and OUD therapeutic, suboxone, suppressed inflammatory cytokine, IL-1β secretion while boosting type I interferon secretion HIV-1-infected microglia. Therefore, clinical opioid receptor antagonists can suppress inflammatory responses that further activate microglia and reduce the risk of microglia adopting a DAM-like phenotype. Our findings show that opioid treatment before and after HIV-1 infection has differential effects on viral replication and innate immune activation. Morphine pretreatment before infection synergizes with the PI3K/Akt pathway to enhance early viral replication steps at reverse transcription, leading to enhanced immunostimulatory viral icRNA expression that triggers inflammatory responses. In contrast, morphine treatment during established HIV-1 infection enhanced both icRNA and msRNA expression along with inflammatory responses that induce a DAM phenotype with potential damaging effects on neuronal structure and synapse plasticity. Collectively, these findings highlight the mechanisms that contribute to increased risks of HAND development in PWH who chronically inject drugs and pave the way for future therapeutics. I propose that targeting MOR activation or the PI3K-Akt pathway could reduce HAND incidence and neuroinflammation in PWH using opioids.

Degree

thesis:*
Name thesis:degree_name
Doctor of Philosophy
Level thesis:degree_level
doctoral
Discipline thesis:degree_discipline
Microbiology
Grantor
Boston University
Year dc:date.issued
2025

Author and committee

dc:creator, dc:contributor.*
Author dc:creator
  • Skeete, Chelsey Alexandra
Advisor dc:contributor.advisor
  • Gummuluru, Suryaram
ORCID dc:identifier.orcid

Subjects

dc:subject × 8

Rights

dc:rights
Statement dc:rights
  • Attribution 4.0 International
Language dc:language.iso
en_US

Identifiers

dc:identifier.*
Handle dc:identifier.uri
https://hdl.handle.net/2144/53153

Chain of custody

source
Harvested from
Boston University
Base URL
open.bu.edu/oai/request
Last updated
2026-11-18
Source record
OAI-PMH GetRecord
citation

Skeete, Chelsey Alexandra. The role of opioid signaling on HIV-1 infection in microglia. doctoral thesis, Boston University, 2025. https://hdl.handle.net/2144/53153